Calmare Therapeutics Incorporated Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
For the nine months period, the company reported revenue of $297,084 compared to $521,530 a year ago. Operating loss was $2,110,639 compared to $1,658,198 a year ago. Loss before income taxes was $2,845,813 compared to $2,746,267 a year ago. Net loss was $2,845,813 or $0.10 per basic and diluted share compared to $2,746,267 or $0.12 per basic and diluted share a year ago. Net cash used in operating activities was $1,135,726 compared to $1,135,726 a year ago. Purchase of property and equipment was $4,700 compared to $47,688 a year ago.